New filings for alogliptin diabetes combination uses in Japan
This article was originally published in Scrip
Executive Summary
Takeda has filed for the approval in Japan of its DPP-4 inhibitor alogliptin for use in combination with either sulphonylurea or biguanide antidiabetic drugs.